This sits right at the intersection of AI capability and biosecurity, and it deserves more attention than a typical demo cycle. The notable part is that the proposed genomes were actually synthesized and produced working phages — a genuine first for genome-scale generative design, even if 'designing life' is generous framing for viruses most biologists hesitate to call alive. The scope was modest: tiny phage genomes, a well-studied bacterial host, no human pathogens involved. But the precedent matters, and the real value of this roundtable is whether the creator addresses the dual-use question head-on — synthesis screening, model access, publication norms. In our view, that conversation is overdue, and the field still lacks a clear rulebook for it.